ES2174851T3 - Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa. - Google Patents

Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.

Info

Publication number
ES2174851T3
ES2174851T3 ES93918326T ES93918326T ES2174851T3 ES 2174851 T3 ES2174851 T3 ES 2174851T3 ES 93918326 T ES93918326 T ES 93918326T ES 93918326 T ES93918326 T ES 93918326T ES 2174851 T3 ES2174851 T3 ES 2174851T3
Authority
ES
Spain
Prior art keywords
ampa receptors
mediaated
pharmaces
synaptic responses
ampa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93918326T
Other languages
English (en)
Inventor
Gary S Lynch
Gary A Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25442213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2174851(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2174851T3 publication Critical patent/ES2174851T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS UTILES PARA INTENSIFICAR LAS RESPUESTAS SINAPTICAS MEDIADAS POR RECEPTORES AMPA, ASI COMO LOS METODOS PARA LA PREPARACION DE LOS MISMOS, Y METODOS PARA SU USO PARA EL TRATAMIENTO DE SUJETOS QUE SUFREN DE FUNCIONAMIENTO NERVIOSO O INTELECTUAL DAÑADO DEBIDO A DEFICIENCIAS EN EL NUMERO DE SINAPSIS EXCITATORIAS O EN EL NUMERO DE RECEPTORES AMPA. LOS COMPUESTOS DE LA INVENCION PUEDEN TAMBIEN SE USADOS PARA EL TRATAMIENTO DE SUJETOS NO DAÑADO PARA INCREMENTAR LA REALIZACION EN TAREAS SENSORIALES-MOTORAS Y COGNITIVAS QUE DEPENDES DE LAS REDES DE LA MENTE UTILIZANDO RECEPTORES AMPA Y PARA MEJORAR LA CODIFICACION DE MEMORIA.
ES93918326T 1992-07-24 1993-07-23 Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa. Expired - Lifetime ES2174851T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91951292A 1992-07-24 1992-07-24

Publications (1)

Publication Number Publication Date
ES2174851T3 true ES2174851T3 (es) 2002-11-16

Family

ID=25442213

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93918326T Expired - Lifetime ES2174851T3 (es) 1992-07-24 1993-07-23 Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
ES01111268T Expired - Lifetime ES2210060T3 (es) 1992-07-24 1993-07-23 Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01111268T Expired - Lifetime ES2210060T3 (es) 1992-07-24 1993-07-23 Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.

Country Status (14)

Country Link
US (2) US5747492A (es)
EP (3) EP1156043B1 (es)
JP (1) JP4374082B2 (es)
KR (1) KR100303523B1 (es)
AT (2) ATE253909T1 (es)
AU (1) AU688271B2 (es)
CA (2) CA2450801C (es)
DE (2) DE69333299T2 (es)
DK (2) DK0651746T3 (es)
ES (2) ES2174851T3 (es)
HK (1) HK1042485B (es)
NZ (2) NZ255097A (es)
PT (2) PT1156043E (es)
WO (1) WO1994002475A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174851T3 (es) 1992-07-24 2002-11-16 Univ California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
US6274600B1 (en) * 1995-06-05 2001-08-14 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
DE69739970D1 (de) * 1996-01-29 2010-10-07 Univ California Methode zur behandlung sexueller fehlfunktionen
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
CA2250856A1 (en) * 1996-04-19 1997-10-30 The Regents Of The University Of California Treatment of mood/affective disorders by glutamatergic upmodulators
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
US6011991A (en) * 1998-12-07 2000-01-04 Technology Patents, Llc Communication system and method including brain wave analysis and/or use of brain activity
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
AU2002320841B2 (en) 2001-06-14 2008-02-28 Merck Sharp & Dohme B.V. (Pyrido/thieno)-[f]-oxazepin-5-one derivatives as positive modulators of the AMPA receptor
US6562972B1 (en) * 2001-07-19 2003-05-13 Air Products And Chemicals, Inc. Method for preparing heterocyclic-carboxylic acids
CZ2004632A3 (cs) * 2001-11-26 2004-08-18 Cortexápharmaceuticalsźáinc Karbonylbenzoxazinové sloučeniny pro zvýšení glutamátergních synaptických odpovědí
EA200501117A1 (ru) 2003-01-13 2006-02-24 Кортекс Фармасеутикалс, Инк. Способ лечения снижения когнитивной способности вследствие лишения сна и стресса
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
EP1960373A2 (en) 2005-11-22 2008-08-27 NeuroSearch A/S Novel quinoxaline derivatives and their medical use
US20100035877A1 (en) * 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
US8039468B2 (en) 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008060375A2 (en) * 2006-10-06 2008-05-22 The Regents Of The University Of Californina Upregulating bdnf levels to mitigate mental retardation
NZ578290A (en) * 2007-01-03 2012-03-30 Cortex Pharma Inc 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
WO2008085506A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
WO2008143963A1 (en) * 2007-05-17 2008-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) * 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
CA2829006A1 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
EP2948135B1 (en) 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
WO2014201411A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SYSTEM AND METHODS FOR ENHANCEMENT OF SLEEP
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456991A (en) * 1946-01-16 1948-12-21 Thompson Boyce Plant Res 3, 4-methylenedioxyphenyl-propylene compound
US2487179A (en) * 1946-08-23 1949-11-08 Thompson Boyce Plant Res Organic compounds
US2773062A (en) * 1953-10-06 1956-12-04 Thompson Boyce Plant Res Organic compounds and insecticidal compositions
FR1534547A (fr) * 1966-08-23 1968-07-26 May & Baker Ltd Nouveaux sels d'ammonium quaternaires de semicarbazones et thiosemicarbazones et leur préparation
US3869431A (en) * 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4083853A (en) * 1973-09-08 1978-04-11 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
CH583730A5 (es) * 1973-09-25 1977-01-14 Wander Ag Dr A
US4025629A (en) * 1974-01-07 1977-05-24 The Upjohn Company P-(trifluoromethylquinolylamino)benzamides, pharmaceutical dosage forms and method of treatment
DE2757483C2 (de) * 1977-12-22 1980-02-28 Haarmann & Leimer Gmbh, 3450 Holzminden Verfahren zur Herstellung von Il-peronylidencrotonsäureamiden
DE2757506C2 (de) * 1977-12-22 1980-02-14 Haarmann & Reimer Gmbh, 3450 Holzminden Verfahren zur Herstellung von Piperonylidencrotonsaureamiden
CU21107A3 (es) * 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
US4209517A (en) * 1978-07-17 1980-06-24 Unicler α-Ethylenic alcohols and ketones, their preparation, and their use as medicaments
FR2461710A1 (fr) * 1979-07-16 1981-02-06 Sarget Sa Labo Nouvelles imines derivees de l'amino-5 benzodioxole-1,3 utiles comme medicaments
DE3009542A1 (de) * 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
CH646149A5 (de) * 1981-02-05 1984-11-15 Hoffmann La Roche Pyrrolidin-derivat.
US4431662A (en) * 1981-03-06 1984-02-14 Hodgson Gordon L Jun 1-(1,3-Benzodioxol-5-yl)-2-pyrrolidinone and its medicinal use
ES8203877A1 (es) * 1981-05-13 1982-04-01 Ferrer Int Procedimiento de obtencion de nuevos aminoderivados en posi-cion 1, del 1-(3',4'-metilendioxifenil)propan-2-ol
US4438142A (en) * 1982-03-05 1984-03-20 Burroughs Wellcome Co. Pharmaceutical combination
US4543361A (en) * 1983-08-29 1985-09-24 Muchowski Joseph M ±2-[Phenethyl]-5-[(3,4-methylenedioxy)-α-hydroxybenzyl]pyrrolidine antihypertensives and use thereas
US4548949A (en) * 1983-01-24 1985-10-22 Syntex (U.S.A.) Inc. +2-[(3,4-Methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-α-hydroxybenzyl]pyrrolidines
US4499100A (en) * 1983-05-18 1985-02-12 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethyleneamino-piperidinyl acetanilides, ketones, esters and carbamates which effect immunity and calcium entry and β-blockade
US4582909A (en) * 1984-02-02 1986-04-15 Warner-Lambert Company Benzobicyclic lactam acids and derivatives as cognition activators
JPS60163812A (ja) * 1984-02-03 1985-08-26 Zenyaku Kogyo Kk 抗アレルギ−剤
IT1215587B (it) * 1987-06-26 1990-02-14 Roussel Maestretti Spa Derivati della 1-benzoil2-oxo 5-alcossi pirrolidina, loro procedimento di preparazione e loro impiego come sostanza medicinale.
US5284876A (en) * 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
JP2842888B2 (ja) * 1989-05-19 1999-01-06 森永製菓株式会社 リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤
IT1231921B (it) * 1989-06-12 1992-01-15 Sigma Tau Ind Farmaceuti 1-acil-2-pirrolidoni quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
SE464275B (sv) * 1989-07-31 1991-04-08 Aagerup Bengt Ny anvaendning av beta-receptorblockerare foer beredning av ett preparat verksamt mot menieres sjukdom
IE910939A1 (en) * 1990-04-13 1991-10-23 Neurosearch As Use of benzodiazepine compounds
FR2669029B1 (fr) * 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP3531944B2 (ja) * 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia
US5104877A (en) * 1991-02-25 1992-04-14 Abbott Laboratories Psoriasis treatment
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4119146C2 (de) * 1991-06-11 2001-01-11 Rehau Ag & Co Polymer-Mischungen Verfahren zu ihrer Herstellung und ihre Verwendung
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US6406868B1 (en) * 1992-06-10 2002-06-18 Nps Allelix Corporation AMPA-binding human GluR1 receptors
ES2174851T3 (es) 1992-07-24 2002-11-16 Univ California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
US6329364B1 (en) * 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
US5852008A (en) 1995-01-24 1998-12-22 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
BR9814106A (pt) 1997-10-27 2000-10-03 Cortex Pharma Inc Processo para tratar da esquizofrenia em um indivìduo, e, conjunto

Also Published As

Publication number Publication date
EP1156043A2 (en) 2001-11-21
EP0651746A1 (en) 1995-05-10
US5891876A (en) 1999-04-06
DE69331761D1 (de) 2002-05-02
NZ510375A (en) 2003-04-29
EP1367056A1 (en) 2003-12-03
EP0651746B1 (en) 2002-03-27
DE69333299T2 (de) 2004-09-09
HK1042485A1 (en) 2002-08-16
CA2450801A1 (en) 1994-02-03
JPH07509468A (ja) 1995-10-19
AU688271B2 (en) 1998-03-12
PT1156043E (pt) 2004-03-31
EP1156043A3 (en) 2001-12-05
CA2450801C (en) 2009-11-17
DK0651746T3 (da) 2002-07-29
KR100303523B1 (ko) 2001-11-22
ES2210060T3 (es) 2004-07-01
CA2138533C (en) 2009-04-14
ATE253909T1 (de) 2003-11-15
WO1994002475A1 (en) 1994-02-03
US5747492A (en) 1998-05-05
JP4374082B2 (ja) 2009-12-02
DE69331761T2 (de) 2002-09-12
HK1042485B (en) 2004-03-05
EP1156043B1 (en) 2003-11-12
PT651746E (pt) 2002-09-30
KR950702550A (ko) 1995-07-29
ATE215079T1 (de) 2002-04-15
CA2138533A1 (en) 1994-02-03
DE69333299D1 (de) 2003-12-18
NZ255097A (en) 2001-04-27
DK1156043T3 (da) 2004-03-01
AU4781593A (en) 1994-02-14

Similar Documents

Publication Publication Date Title
ES2174851T3 (es) Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
ES2130166T3 (es) Reduccion de la interaccion de pesticidas en cosechas.
MX9205443A (es) 4-alcoxi-pirimidinas sustituidas, procedimientos para su preparacion, agentes que las contienen, y su utilizacion como agentes plaguicidas.
ES2126566T3 (es) 1-arilpirazoles plaguicidas.
AR225436A1 (es) Oxazoliloxi-,oxadiazoliloxi-,tiazoliloxi- y tiadizoliloxi-carboxilamidas,procedimiento para su produccion y composiciones herbicidas que las contienen
BR9100441A (pt) Compostos de tipo triazolpiridina,composicoes herbicidas,processo para a erradicacao de ervas daninhas,compostos utilzavel como intermediarios,processos para a preparacao de compostos e utilizacao dos compostos como herbicidas
ES2123553T3 (es) Compuestos fluoroalquenilo y su uso como repelentes de plagas.
MX9203279A (es) 1-aril-2-acilamido-3-fluoro-1-propanoles, metodos para su uso como agentes antibacterianos y composiciones utiles de los mismos.
BG48682A3 (en) Herbicid means and method for struggle with weeds
ES2059841T3 (es) Nitro compuestos con actividad insecticida.
BR9104045A (pt) Composto,processos para sua preparacao,composto intermediario,composicao herbicida,processo para exterminio de ervas daninhas indesejadas e uso do dito primeiro composto
BR8600949A (pt) Ester inseticidamente ativo,processo para combater pragas de insetos e processo para preparar o ester inseticidamente ativo
BR8304777A (pt) Composto heterociclico, composicao herbicida, processo para matar ervas daninhas e processo para produzir o composto
BR9404147A (pt) Composto dihalopropeno, inseticida/acaricida, método para controlar pragas de insetos nocivos, uso do dito composto, processo para produzir o mesmo e composto intermediário
AR225474A1 (es) Tetrazol-5-iloxi-acetamidas,procedimiento para su obtencion y composiciones herbicidas que las contienen
BR8100596A (pt) Derivados de 2-nitro-5-(substituido-fenoxi) benzoila, compsicao herbicida e processo para combater ervas daninhas
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
MX9102117A (es) Metodo para el tratamiento de nematodos en terreno, empleando furfural.
BG40956A3 (bg) Средство и метод за борба с паразитиращи върху пчели акари
AR000483A1 (es) Un método para reprimir el crecimiento de malezas composiciones herbicidas de aplicación en dicho método
FI880102L (fi) Herbisidisiä väkevöityjä N-(1-etyylipropyyli)-2,6-dinitro-3,4-ksylidiinin öljy vedessä -emulsiokoostumuksia ja menetelmä niiden valmistamiseksi
BG30914A3 (en) Incecticide means and method for insects fighting
BR7800781A (pt) Processo para preparacao de cloro-acetanilidas herbicidas,processo para a preparacao de anilidas e processo para combater infestacoes em monotiledoneas e dicotiledoneas
BR8000277A (pt) Fenoxi-e tiofenoxinitrilas,processo para sua obtencao,processo para tratamento anti-gramineas,bem como herbicida,pomolhavel,e concentrado emulsionavel
BG33881A3 (en) Herbicide means and method for cultural plants treatment

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 651746

Country of ref document: ES